UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 14, 2015
SORRENTO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-36150 |
|
33-0344842 |
|
(State or other jurisdiction |
|
(Commission File Number) |
|
IRS Employer |
|
of incorporation or organization) |
|
|
|
Identification No.) |
9380 Judicial Drive
San Diego, CA 92121
(Address of principal executive offices)
Registrant’s telephone number, including area code: (858) 210-3700
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13e-4©)
EXPLANATORY NOTE
On May 15, 2015, Sorrento Therapeutics, Inc. (“Sorrento”) filed a Current Report on Form 8-K under Item 1.01 (the “Initial Report”) to report the sale to NantPharma, LLC of all of the Company’s equity interests in IgDraSol, Inc. (the “Transaction”). This Current Report on Form 8-K/A amends Items 9.01(b) of the Initial Report to provide pro forma financial information related to the Transaction. Except as stated in this Explanatory Note, no other information contained in the Initial Report is changed.
Item 9.01 Financial Statements and Exhibits.
(b) Pro Forma Financial Information.
Unaudited pro forma condensed consolidated financial information is filed as Exhibit 99.3 to this Current Report.
(d)Exhibits
|
Exhibit No. |
Description |
|
99.3 |
Unaudited Pro Forma Condensed Consolidated Financial Information. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 5, 2016
|
|
SORRENTO THERAPEUTICS, INC. |
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Henry Ji |
|
|
|
Name: Henry Ji |
|
|
|
Title: President and Chief Executive Officer |